Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans
Here, Khurana et al. report the results of a phase 4 clinical trial with three FDA approved influenza vaccines and show that repeat influenza vaccination results in reduced antibody affinity maturation to hemagglutinin domain 1 irrespective of vaccine platform.
Main Authors: | Surender Khurana, Megan Hahn, Elizabeth M. Coyle, Lisa R. King, Tsai-Lien Lin, John Treanor, Andrea Sant, Hana Golding |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2019-07-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-019-11296-5 |
Similar Items
-
AID activity in B cells strongly correlates with polyclonal antibody affinity maturation in-vivo following pandemic 2009-H1N1 vaccination in humans.
by: Surender Khurana, et al.
Published: (2012-09-01) -
Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization.
by: Surender Khurana, et al.
Published: (2014-01-01) -
Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization.
by: Surender Khurana, et al.
Published: (2015-01-01) -
Autoreactivity of Broadly Neutralizing Influenza Human Antibodies to Human Tissues and Human Proteins
by: Surender Khurana, et al.
Published: (2020-10-01) -
Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex
by: Juanjie Tang, et al.
Published: (2021-12-01)